Clinical trials: Immunodeficiency
HIV Infections
Phase I/II Study of Curdlan Sulfate
To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses…
- Trial name
- NCT00002100
- Testing
- Curdlan sulfate
- Where
- United States
- Sponsor
- AJI Pharma USA
HIV Infections
Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring
The proposed study is a single center, double-blind placebo-controlled trial to assess the safety and tolerability of the dapivirine ring as compared to a placebo ring when inserted for 28 days in 16 healthy, HIV-negative women.
- Trial name
- NCT02920827
- Testing
- Dapivirine Vaginal Ring
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Parkinson's Disease, HIV Infections
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
This pilot study will assess the feasibility of using heavy water as a safe 'tracer' for biomarker studies of diseases of the brain and spinal cord, that, together, are also called the central nervous system (CNS).
- Trial name
- NCT00990379
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Salena Killion
HIV Infections
A Study of DTC in Patients With AIDS and AIDS Related Complex
To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents…
- Trial name
- NCT00002069
- Testing
- Ditiocarb sodium
- Where
- 8 sites in United States
- Sponsor
- Merieux Institute
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: If taking MK-8527 once a month works to prevent HIV-1 infection as well as or…
- Trial name
- NCT07044297
- Testing
- MK-8527, FTC/TDF
- Where
- 81 sites in United States, Argentina and 14 more
- Volunteers
- 4,390 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hereditary Angioedema (HAE)
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
The purpose of this study is to assess the efficacy and safety of subcutaneous administration of a liquid formulation of C1 esterase inhibitor for the prevention of angioedema attacks in adolescent and adult subjects with…
- Trial name
- NCT02584959
- Testing
- C1 esterase inhibitor [human] liquid
- Where
- 27 sites in United States, Canada and 5 more
- Volunteers
- 75 people
- Sponsor
- Shire
Human Immunodeficiency Virus (HIV) Infections
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
The primary objective of this study is to evaluate the safety and tolerability of Islatravir (ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming hormone therapy (GAHT) and are at low-risk for…
- Trial name
- NCT05130086
- Testing
- Islatravir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
This study uses autologous (one's own) CD4 T cells modified with a viral vector expressing a genetic antisense targeting HIV, this vector is called VRX496.
- Trial name
- NCT00131560
- Testing
- VRX496-Modified Autologous T cells
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- VIRxSYS Corporation
HIV Infections
A Study of Two Anti-HIV Drug Combinations
The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI.
- Trial name
- NCT00002203
- Testing
- Lamivudine/Zidovudine, Lamivudine, Zidovudine
- Where
- 7 sites in United States, Puerto Rico
- Sponsor
- Glaxo Wellcome
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human…
- Trial name
- VOYAGE-1 (NCT03222583)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 48 sites in China, Singapore and 1 more
- Volunteers
- 546 people
- Sponsor
- AbbVie
HIV Infections
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
This prospective observational study will evaluate predictors of response to Invirase (saquinavir) treatment in treatment-naïve patients with HIV infection. Data will be collected during 48 weeks of treatment.
- Trial name
- NCT01297127
- Where
- 8 sites in Poland
- Volunteers
- 151 people
- Sponsor
- Hoffmann-La Roche
Human Immunodeficiency Virus (HIV)
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.
- Trial name
- NCT00992654
- Testing
- Open Label Treatment Access: Maraviroc
- Sponsor
- ViiV Healthcare
HIV Positive
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
The health of the immune system in HIV infected people is currently determined from a blood test measuring the number of cluster of differentiation 4 (CD4) T lymphocytes. These cells play a critical role in an immune response.
- Trial name
- QFM (NCT01904201)
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- QIAGEN Gaithersburg, Inc
Infection, Human Immunodeficiency Virus, HIV Infections
Phase 4 Study of Dolutegravir (DTG) in Russian Federation
DTG 50 milligram (mg) tablet was approved for marketing in Russian Federation; however, DTG is not currently available for subjects at Acquired Immune Deficiency Syndrome (AIDS) Centers as it is not available for order and supply…
- Trial name
- NCT03314064
- Testing
- Dolutegravir 50 mg
- Where
- 11 sites in Russia
- Volunteers
- 43 people
- Sponsor
- ViiV Healthcare
HIV Infections
Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®
Collecting data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) after switching from protease inhibitor or NNRTI to Nevirapine (Viramune®) and collecting of…
- Trial name
- NCT02191293
- Testing
- Viramune® tablets
- Volunteers
- 228 people
- Sponsor
- Boehringer Ingelheim
Primary Immunodeficiency Disease
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).
- Trial name
- CARES10 (NCT03961009)
- Testing
- Kedrion IVIG 10%
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Kedrion S.p.A.
HIV Infections
A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients
To determine the MTD and dose-limiting toxicities of recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously in HIV-seropositive patients.
- Trial name
- NCT00002107
- Testing
- Aldesleukin
- Where
- United States
- Sponsor
- Chiron Corporation
HIV Infections
Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)
Compassionate use access to fostemsavir (GSK3684934, formerly BMS-663068) for the treatment of HIV infection in individuals with multidrug resistant HIV-1 infection who are experiencing virologic failure and are unable to…
- Trial name
- NCT04233047
- Testing
- Fostemsavir
- Sponsor
- ViiV Healthcare
HIV Infections
3TC (Lamivudine; GR109714X) Open-Label Program
To make lamivudine (3TC) available to patients with progressive, symptomatic HIV disease who cannot participate in a controlled clinical trial and who are refractory or unable to tolerate other therapies.
- Trial name
- NCT00002108
- Testing
- Lamivudine, Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome